The key finding
Researchers analyzed 205 clinical studies on 42 traditional Chinese patent medicines (CPMs) used to treat stable chronic obstructive pulmonary disease (COPD), a progressive lung condition affecting millions worldwide. They found these herbal formulations are extensively applied in clinical practice, with Bailing Capsules accounting for 26.70% of published studies. However, the analysis revealed serious quality gaps: only 32.46% of studies properly classified patients according to Traditional Chinese Medicine diagnostic principles, and most studies lacked adequate safety reporting, randomization procedures, and long-term follow-up data. Of the 205 studies examined, 181 were randomized controlled trials, though methodological rigor was generally poor across the research landscape.
What the study looked like
This was a comprehensive evidence mapping study — essentially a bird’s-eye view of all available research rather than a single clinical trial. Researchers searched eight major databases through November 2024, capturing studies published in both Chinese (203 studies) and English (2 studies). The 205 included studies comprised 181 randomized controlled trials, 8 non-randomized trials, 2 case-control studies, 9 systematic reviews or meta-analyses, and 5 clinical guidelines or expert consensus documents. The researchers examined publication trends, how studies classified patients using TCM diagnostic categories, what interventions were tested, which outcomes were measured, and the overall quality of study methods. This approach allowed them to identify patterns, gaps, and quality issues across the entire body of research on oral Chinese medicines for stable COPD.
Why researchers think this happened
The study authors suggest the methodological weaknesses stem from several factors in how traditional medicine research has evolved. Many CPMs entered clinical use based on historical practice patterns rather than modern evidence standards, leading to ambiguous clinical indications and incomplete safety documentation. The low utilization of TCM syndrome differentiation (only about one-third of studies) likely reflects a disconnect between traditional diagnostic principles and contemporary research design. Researchers noted heterogeneous outcome measures across studies, with most focusing on conventional medical endpoints like pulmonary function tests while neglecting TCM-specific outcomes and patient-reported quality of life measures. The lack of blinding and inadequate randomization procedures may reflect practical challenges in conducting rigorous trials within traditional medicine frameworks, as well as limited research funding and methodological training.
How to read this carefully
This is not a study of whether these medicines work — it’s an analysis of the quality of existing research. The finding that CPMs “demonstrated remarkable therapeutic efficacy” should be interpreted cautiously, as the researchers themselves note the studies had major quality limitations. Poor randomization, lack of blinding, and incomplete reporting mean many included studies may overestimate benefits. The analysis was limited to published literature, which may miss negative results that never reached publication. Additionally, 99% of studies were in Chinese, potentially limiting international verification. Most importantly, this evidence map cannot tell us which specific CPMs are safe or effective for COPD — only that the current research base is inadequate to make strong conclusions. The association between CPM use and outcomes in these studies does not establish causation.
What this means for everyday life
For people living with COPD or their caregivers, this analysis highlights an important reality: traditional Chinese medicines are widely used for chronic lung conditions, but the evidence base supporting them needs significant improvement. If you’re considering complementary approaches to COPD management, this research suggests asking specific questions about safety data and how treatments align with TCM diagnostic principles, since most studies overlooked these elements. The findings emphasize that gaps in research quality don’t necessarily mean treatments don’t work — but they do mean we need better evidence before making informed decisions. Given that COPD requires long-term management and affects quality of life profoundly, this study’s call for standardized outcome measures and economic evaluations points toward what patients actually need: evidence that addresses real-world concerns about safety, cost, and sustained benefits over years, not just short-term symptom changes.